STELARA (also known as Ustekinumab)
Mechanism:
Stelara is an antibody that targets Interleukin 12 and 23, which are both important chemical messengers that activate T-cells. Stelara is designed to reduce inflammatory processes.
Indications:
Contraindications:
Patients with active infection should not be started on Stelara.
Administration:
For patients with plaque psoriasis and psoriatic arthritis, Stelara can be administered as a subcutaneous injection at week 0, 4, and every 12 weeks thereafter. For patients with Crohn’s Disease, Stelara is typically administered and initiated as a single intravenous infusion dose; for maintenance, Stelara can be administered as a subcutaneous injection every 8 weeks thereafter.